Results 201 to 210 of about 49,840 (301)

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

open access: yesCA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract Although poly(adenosine diphosphate‐ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first‐line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA‐mutated/homologous recombination‐deficient (HRD) patients, is lacking.
Lingying Wu   +56 more
wiley   +1 more source

Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment

open access: yes, 2020
Berger, H.   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy